ArticleHealth research policy and systems2026
Catalysing vaccines research, development and manufacturing in Nigeria: a qualitative exploration of industry stakeholders' knowledge, perceptions and experience.
Article in Health research policy and systems, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe lack of local production of vaccines in Nigeria is a challenge contributing to limited access to healthcare. To address these vulnerabilities, the nation has committed efforts toward vaccine self-sufficiency through local production. However, this initiative has been met with a plethora of constraints. These include inadequate technical capacity, insufficient resources, limited infrastructure, procurement challenges, cold chain management, uncertain market mechanisms and a lack of funding. This study, therefore, aims to bridge this gap by articulating robust strategies for local vaccine production from the perspective of relevant stakeholders across different areas of the vaccine value chain.
methodsA qualitative strategy was adopted to explore participants' perspectives on the strategies for sustainable local vaccine manufacturing in Nigeria. The study sample represented stakeholders practising across different areas of the vaccine value chain. Data obtained were analysed thematically to yield themes and sub-themes. Trustworthiness in the study was ensured through recommended frameworks.
resultsFollowing data analysis, nine overarching themes were identified, which articulated the need to build capacity and an enabling environment for vaccine development in Nigeria. The findings showed that inadequate research capacity, weak infrastructure and poor commercialization frameworks constrain vaccine production, necessitating phased production initiation, strengthened research systems, infrastructural development and improved market access. Effective management and advocacy were found to be critical for securing government and stakeholders' commitment, as well as reducing vaccine hesitancy to support sustainable local vaccine production.
conclusionsThis study provides in-depth insights into the strategies for expediting the national objective to achieve vaccine self-sufficiency, including the establishment of an enabling policy and legislative environment to attract investment, streamline regulation and secure market access for locally produced vaccines. It emphasizes strengthening research and development capacity beyond fill-and-finish activities, addressing workforce skills gaps through training and technology transfer, and improving infrastructure through reliable power supply and vaccine industrial parks. Overall, the findings highlight the need for sustainable financing, stakeholder coordination, and strong government interventions to ensure the viability of local vaccine manufacturing. These insights can guide effective planning and comprehensive efforts into the requisite areas necessary for sustainable vaccine manufacturing in the country.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.